Moreno Evelyn V Acquires 1,625 Shares of CVS Health Corp (CVS)

Moreno Evelyn V lifted its holdings in CVS Health Corp (NYSE:CVS) by 1.7% in the 3rd quarter, HoldingsChannel reports. The fund owned 96,056 shares of the pharmacy operator’s stock after buying an additional 1,625 shares during the quarter. CVS Health comprises approximately 2.3% of Moreno Evelyn V’s portfolio, making the stock its 14th largest holding. Moreno Evelyn V’s holdings in CVS Health were worth $7,812,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Fieldpoint Private Securities LLC grew its holdings in CVS Health by 333.3% during the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock valued at $105,000 after purchasing an additional 1,000 shares in the last quarter. Arcadia Investment Management Corp MI grew its holdings in CVS Health by 119.6% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock valued at $108,000 after purchasing an additional 726 shares in the last quarter. MPS Loria Financial Planners LLC acquired a new stake in CVS Health during the 2nd quarter valued at $119,000. Gemmer Asset Management LLC grew its holdings in CVS Health by 15.3% during the 2nd quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock valued at $121,000 after purchasing an additional 200 shares in the last quarter. Finally, Captrust Financial Advisors acquired a new stake in CVS Health during the 2nd quarter valued at $155,000. 81.62% of the stock is owned by institutional investors.

CVS Health Corp (CVS) opened at $78.78 on Friday. The firm has a market cap of $79,803.51, a price-to-earnings ratio of 16.28, a price-to-earnings-growth ratio of 1.25 and a beta of 0.90. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. CVS Health Corp has a fifty-two week low of $66.45 and a fifty-two week high of $84.72.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.49 by $0.01. The company had revenue of $46.18 billion during the quarter, compared to analyst estimates of $46.17 billion. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period last year, the business earned $1.64 EPS. sell-side analysts predict that CVS Health Corp will post 5.89 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 2nd. Shareholders of record on Wednesday, January 24th will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 2.54%. The ex-dividend date of this dividend is Tuesday, January 23rd. CVS Health’s dividend payout ratio is currently 41.32%.

In other CVS Health news, EVP Lisa Bisaccia sold 29,445 shares of the firm’s stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the transaction, the executive vice president now directly owns 15,556 shares of the company’s stock, valued at approximately $1,166,700. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.61% of the stock is owned by company insiders.

A number of equities research analysts recently weighed in on the stock. Royal Bank of Canada assumed coverage on shares of CVS Health in a report on Tuesday, September 19th. They set an “outperform” rating and a $95.00 price target for the company. ValuEngine lowered shares of CVS Health from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Robert W. Baird reaffirmed a “hold” rating and set a $77.00 price target on shares of CVS Health in a report on Friday, October 27th. Mizuho set a $90.00 price target on shares of CVS Health and gave the company a “buy” rating in a report on Tuesday, October 24th. Finally, Leerink Swann raised their price target on shares of CVS Health from $82.00 to $90.00 and gave the company an “outperform” rating in a report on Monday, January 8th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $86.66.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.com-unik.info/2018/01/14/moreno-evelyn-v-acquires-1625-shares-of-cvs-health-corp-cvs.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

What are top analysts saying about CVS Health? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CVS Health and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit